Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction (2022)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1016/j.jchf.2021.08.006
- Subjects: INSUFICIÊNCIA CARDÍACA; FÁRMACOS SINTÉTICOS; MORTALIDADE HOSPITALAR
- Agências de fomento:
- AstraZenecaAstraZeneca
- British Heart Foundation Centre of Research Excellence Grant [RE/18/6/34217]
- University Hospital Foundation
- PfizerPfizer
- NovartisNovartis
- Vifor Pharma
- BayerBayer AG
- Esperion
- CLS Behring
- DalCor
- JanssenJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc
- Novo NordiskNovo Nordisk
- Sanofi
- AmgenAmgen
- Boehringer IngelheimBoehringer Ingelheim
- MerckMerck & Company
- Bristol Myers SquibbBristol-Myers Squibb
- Daiichi-SankyoDaiichi Sankyo Company Limited
- EisaiEisai Co Ltd
- GlaxoSmithKlineGlaxoSmithKline
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Jacc-heart failure
- ISSN: 2213-1779
- Volume/Número/Paginação/Ano: v. 10, n. 1, p. 52-64, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by
-
ABNT
DOCHERTY, Kieran F et al. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, v. 10, n. 1, p. 52-64, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006. Acesso em: 20 abr. 2024. -
APA
Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Diez, M., Howlett, J. G., et al. (2022). Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, 10( 1), 52-64. doi:10.1016/j.jchf.2021.08.006 -
NLM
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 abr. 20 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006 -
Vancouver
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 abr. 20 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1016/j.jchf.2021.08.006 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
